Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed and are effective for treating inflammatory arthritis. Their therapeutic benefits are accompanied by clinically significant gastrointestinal side effects including dyspepsia, gastroduodenal ulcers, and the associated complications of haemorrhage and perforation. Fries et al i have shown in a large number of patients with computerised clinical records that there is a relatively unfavourable risk/benefit ratio for the long term use of NSAIDs due to gastrointestinal toxicity. There is, however, the potential to prevent some of this toxicity by co-prescribing the synthetic prostaglandin misoprostol. Overviews have given conflicting advice about the value of misoprostol for the prophylaxis of NSAID induced gastroduodenal damage. Soil et al 2 thought the balance of evidence was in favour of prophylaxis with misoprostol especially in some groups at high risk ofgastroduodenal damage. By contrast Barrison3 suggested there is no benefit to be gained from long term prophylaxis.
When should misoprostol be used? To resolve this issue we have reconsidered the incidence, pathogenesis, treatment, and prevention of NSAID induced gastroduodenal damage, focusing on the role of misoprostol and its advantages and drawbacks. 24 Treatment of NSAID associated ulcers When patients develop gastrointestinal ulceration while receiving NSAIDs it is best to stop treatment wherever possible and heal the ulcer. In this situation misoprostol will heal 95% of gastric ulcers after four weeks of treatment compared with 75% healing in placebo treated patients. 25 Although there have been no comparative trials of misoprostol and H2 blockers, in a similar study cimetidine achieved only 71% healing after four weeks of treatment. 26 When it is clinically preferable to continue the treatment with NSAIDs, misoprostol is the treatment of choice to achieve ulcer healing. Roth et al showed that misoprostol coadministered with aspirin is effective in healing aspirin associated gastroduodenal damage in patients with rheumatoid arthritis27; 238 patients received a baseline endoscopy and were then randomised to receive either misoprostol or placebo while continuing treatment with aspirin. After eight weeks healing of gastric mucosal injury had occurred in 70% of the misoprostol treated group compared with 25% of the placebo treated subjects. Gastric ulceration was reduced in the misoprostol treated group; by eight weeks the healing rates were 62% in misoprostol treated subjects compared with 32% receiving placebo. Duodenal injury healed in 86% of the misoprostol treated group and 53% receiving placebo. Of these only 18 patients had duodenal ulcers on the baseline endoscopy; by eight weeks healing was seen in 90% receiving misoprostol and in 50% of controls.
Most 5 recruited patients with osteoarthritis receiving NSAIDs who at an initial endoscopy were free of gastric ulceration. Patients were randomly assigned to misoprostol (100-200 pg four times daily) or placebo during continued treatment with NSAIDs; repeat endoscopy was performed at one, two, and three months. The cumulative three month prevalence of gastric ulceration was 22% in the placebo group, 6% in the 100 pg misoprostol group, and only 1% in patients receiving 200 [tg misoprostol. The two doses of misoprostol were significantly better than placebo. In a 12 month study the cumulative prevalence of gastric ulceration was 12-5% in the group of patients receiving misoprostol (600-800 R,g/day), compared with 30% in the group receiving placebo (p<0r05). 23 Studies with H2 antagonists have produced variable results in placebo controlled trials. In normal volunteers cimetidine prevented acute gastric mucosal injury induced by a single dose of aspirin43 but was not effective in reducing gastroduodenal erosions or ulcers in a one week trial during coadministration with naproxen.4 Table 2 shows potential indications for coadministration of misoprostol with NSAIDs.
Unanswered questions
The most important question is whether coprescribing misoprostol with NSAIDs reduces the occurrence of serious life threatening complications of gastroduodenal damage. The logical extrapolation from the endoscopic studies is that it is likely to be so, but there is no direct evidence that this is true. The principal 
